LCMS-9030 Q-TOF for peptide mapping and structural characterization of mAb biosimilars
Therapeutic monoclonal antibody (mAb) biosimilars are booming in Asia and across the world, as well as faces significant challenges in quality control.
Peptide mapping plays a critical role in structure characterization of antibody drugs. This webinar will introduce 4 Application News for structure characterization of bevacizumab biosimilar using LCMS-9030 Q-TOF mass spectrometry, including peptide mapping, C-terminal sequencing, disulfide bond analysis, and N-glycan analysis.
Learning Objectives:
Understand the critical quality attributes of biosimilar mAb
Explore how LCMS-QTOF can be used to characterize Bevacizumab biosimilar (Peptide mapping, terminal sequencing, disulfide bonds and N-glycan analysis)
Presenter: Lu Yonghai (Ph.D.) (Senior Application Chemist, Shimadzu (Asia Pacific) Pte Ltd)
Lu earned his PhD degree in Biology from the Chinese University of Hong Kong. In September 2018, Lu joined Shimadzu (Asia Pacific) as a Senior Application Chemist in Life Science and Advanced MS. Prior to working at Shimadzu, Lu was a Senior Scientist at the National University of Singapore in a Multi-Omics research lab specializing in LC-MS and GC-MS analysis.
